Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals Inc. Fundamental Analysis
Aurinia Pharmaceuticals Inc. (AUPH) shows strong financial fundamentals with a PE ratio of 7.30, profit margin of 1.01%, and ROE of 70.37%. The company generates $0.3B in annual revenue with strong year-over-year growth of 33.97%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 85.2/100 based on profitability, valuation, growth, and balance sheet metrics. The B+ grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze AUPH's fundamental strength across five key dimensions:
Efficiency Score
ExcellentAUPH demonstrates superior asset utilization.
Valuation Score
ExcellentAUPH trades at attractive valuation levels.
Growth Score
ModerateAUPH shows steady but slowing expansion.
Financial Health Score
ExcellentAUPH maintains a strong and stable balance sheet.
Profitability Score
ModerateAUPH maintains healthy but balanced margins.
Key Financial Metrics
Is AUPH Expensive or Cheap?
P/E Ratio
AUPH trades at 7.30 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, AUPH's PEG of 0.03 indicates potential undervaluation.
Price to Book
The market values Aurinia Pharmaceuticals Inc. at 3.61 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 14.62 times EBITDA. This signals the market has high growth expectations.
How Well Does AUPH Make Money?
Net Profit Margin
For every $100 in sales, Aurinia Pharmaceuticals Inc. keeps $1.01 as profit after all expenses.
Operating Margin
Core operations generate 37.06 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $70.37 in profit for every $100 of shareholder equity.
ROA
Aurinia Pharmaceuticals Inc. generates $38.21 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Aurinia Pharmaceuticals Inc. generates strong operating cash flow of $133.16M, reflecting robust business health.
Free Cash Flow
Aurinia Pharmaceuticals Inc. generates strong free cash flow of $132.92M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $1.00 in free cash annually.
FCF Yield
AUPH converts 6.47% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
7.30
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.03
vs 25 benchmark
P/B Ratio
Price to book value ratio
3.61
vs 25 benchmark
P/S Ratio
Price to sales ratio
7.33
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.13
vs 25 benchmark
Current Ratio
Current assets to current liabilities
5.25
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.70
vs 25 benchmark
ROA
Return on assets percentage
0.38
vs 25 benchmark
ROCE
Return on capital employed
0.16
vs 25 benchmark
How AUPH Stacks Against Its Sector Peers
| Metric | AUPH Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 7.30 | 28.45 | Better (Cheaper) |
| ROE | 70.37% | 763.00% | Weak |
| Net Margin | 101.47% | -45265.00% (disorted) | Strong |
| Debt/Equity | 0.13 | 0.34 | Strong (Low Leverage) |
| Current Ratio | 5.25 | 2795.60 | Strong Liquidity |
| ROA | 38.21% | -16588.00% (disorted) | Strong |
AUPH outperforms its industry in 5 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Aurinia Pharmaceuticals Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
47980.87%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
103.02%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
145.49%
Industry Style: Defensive, Growth, Innovation
High Growth